Home > News

New Horizon Health and Prenetics reach a partnership

2022/5/24 14:33:50 Views:176

On May 23, New Horizon Health (6606.HK) and Prenetics Group Limited (NASDAQ: PRE, Prenetics for short) jointly announced a strategic cooperation to promote the listing of cancer early screening product ColoClear in Hong Kong and "going overseas" to Southeast Asia.


According to the signed strategic cooperation agreement, New Horizon Health and Prenetics will start in-depth cooperation, fully integrate the high-quality resources of both parties in market and channel expansion and product and service operation, and jointly promote ColoClear(KRAS gene mutation and BMP3/NDRG4 gene methyl group) Chemical and fecal occult blood combined detection kit) in Hong Kong, Macau, Taiwan, and market coverage, and plans to explore market opportunities in other Southeast Asian countries or regions during the same period. On June 8, ColoClear will be officially listed on the Hong Kong market. During the cooperation period, ColoClear is the colorectal cancer early screening product exclusively cooperated by Prenetics.


Based on the profit distribution agreement reached by the two parties, New Horizon Health and Prenetics will share the profits from ColoClear's sales in the cooperative market in a ratio of 50:50. According to the completed ColoClear authorization agreement, Prenetics has obtained the authorization of New Horizon Health to provide ColoClear central laboratory testing services within the specified market scope.


About New Horizon Health

New Horizon Health was established in 2015. It is a bio-tech company focusing on early screening of high-incidence cancers at home in China. It is also the pioneer and leader in the domestic cancer screening market in China. It aims to promote the innovation of cancer screening technology and accelerate cancer screening. Popularity of screening technology in China. On February 18, 2021, New Horizon Health took the lead in the cancer early screening industry and was successfully listed on the Hong Kong Stock Exchange, with the stock code 6606.HK.

About Prenetics

Founded in 2014, Prenetics is a major global diagnostics and genetic testing company with the mission to bring health closer to millions of people globally and decentralize healthcare by making the three pillars — Prevention, Diagnostics and Personalized Care — comprehensive and accessible to anyone, at anytime and anywhere.